Skip to content
Portage BioTech, LLC.
Portage BioTech, LLC.Portage BioTech, LLC.
  • about us
  • pipeline
  • our products
    • iOx Therapeutics
    • Intensity Therapeutics
    • Nekonal Oncology
    • Rift Biotherapeutics
    • Stimunity
    • Saugatuck Therapeutics / Oncomer
    • other companies
  • leadership
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • press releases
  • contact
  • about us
  • pipeline
  • our products
    • iOx Therapeutics
    • Intensity Therapeutics
    • Nekonal Oncology
    • Rift Biotherapeutics
    • Stimunity
    • Saugatuck Therapeutics / Oncomer
    • other companies
  • leadership
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • press releases
  • contact

press releases

  • Home
  • stock information
  • company Information and policies
  • financial and regulatory reports
  • shareholder circular
  • press releases

PORTAGE BIOTECH PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND ANNOUNCES NASDAQ LISTING APPROVAL

read more

PORTAGE ANNOUNCES FILING OF Q1 INTERIM FINANCIAL STATEMENTS; CORRECTION TO SALVARX LOAN NOTE SETTLEMENT ANNOUNCEMENT

read more

PORTAGE ISSUES COMMON SHARES AND WARRANTS IN SETTLEMENT OF SALVARX LOAN NOTE OBLIGATIONS

read more

PORTAGE ANNOUNCES RELIANCE ON TEMPORARY REGULATORY RELIEF FOR FILING ANNUAL FINANCIAL STATEMENTS

read more

PORTAGE ANNOUNCES RESULTS OF ANNUAL MEETING; PRIVATE PLACEMENT UPDATE; CORPORATE UPDATE

read more

PORTAGE RAISES MORE THAN US$6.7 MILLION THROUGH NON-BROKERED PRIVATE PLACEMENT; TEMPORARY SYMBOL CHANGE ON OTC MARKETS

read more

PORTAGE ANNOUNCES SHARE CONSOLIDATION (REVERSE SPLIT) EFFECTIVE DATE

read more

PORTAGE ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

read more

Portage is pleased to announce the appointment of Allan L. Shaw as CFO

read more

PORTAGE MAKES ADDITIONAL INVESTMENT IN STIMUNITY S.A.S, A PARIS-BASED CANCER IMMUNOTHERAPY COMPANY.

read more

Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept

read more

PORTAGE ANNOUNCES CEASE TRADE ORDER REVOKED; UPDATE ON IMPACT OF COVID-19 ON OPERATIONS

read more

Portage provides update on portfolio company, Intensity Therapeutics, Inc.

read more

Portage Files Business Acquisition Report

read more

PORTAGE ANNOUNCES FILING OF 3RD QUARTER FINANCIAL STATEMENTS AND PROVIDES UPDATE ON CTO REVOCATION APPLICATION AND OTC TRADING

read more

PORTAGE ANNOUNCES FURTHER SUBSCRIPTION OF US$950,000 IN CONVERTIBLE LOAN NOTES TO IOX THERAPEUTICS AND PROVIDES UPDATE ON CTO REVOCATION APPLICATION

read more

2018 audit

read more

Portage Biotech Inc. (CSE: PBT.U, OTC Markets: PTGEF) (“Portage” or the “Company”) is pleased to announce that it has been granted an extension by the Canadian Securities Exchange (the “CSE”) to remedy its default under CSE listing rules.

read more

Portage Announces Change of CEO

read more

Portage makes additional investment in Stimunity S.A. a Paris-Based Cancer immunotherapy company

read more

Portage Announces Change of Auditors

read more

CSE to Issue Final Bulletin Regarding SalvaRx Acquisition

read more

Portage provides updates on trading of its shares on OTC Markets

read more

Shareholders approve Acquisition of SalvaRx Limited

read more

Portage Provides Additional Information on SalvaRx acquisition

read more

Further subscription of US$950,000 in Convertible Loan to iOx

read more

Portage announces setting of meeting date to approve SalvaRx acquisition

read more

Portage posts meeting materials; trading on CSE expected to resume shortly; overview of combined Portage/SalvaRx portfolio

read more

Portage provides update on proposed acquisition of SalvaRx

read more

Portage Provides update on proposed acquisition of SalvaRx

read more

Portage to Acquire SalvaRx Limited

read more

Portage Provides Update on its Associate, Stimunity

read more

Portage invests in IOX Therapeutics

read more

Portage Invests in Stimunity SA

read more

Completion of Stock Dividend

read more

Joint Venture with University of Glasgow

read more

PORTAGE PROVIDES UPDATE ON THEIR DECLARATION OF STOCK DIVIDEND OF BIOHAVEN SHARES

read more

Portage Announces Declaration of Stock Dividend

read more

Updated: Portage Announces its Intention for its Biohaven Shares

read more

Important Tax Notice to U.S. Shareholders of Portage Biotech Inc.

read more

Portage Announces its Intention for its Biohaven Shares

read more

Portage Announces Results of Shareholders Meeting and Provides Update on Its Portfolio Companies

read more

Biohaven announces closing of initial public offering and full exercise of underwriters’ option to purchase additional shares

read more

Portage’s holding in Biohaven

read more

Biohaven announces pricing of its initial public offering of common shares

read more

Portage provides updates on its Portfolio companies

read more

Biohaven files registration statement for proposed public offering of its common shares

read more

Portage Announces Spinout of Eygen Limited

read more

Biohaven Raises $80 Million in Private Financing

read more

Press Release on Chairman’s Letter

read more

Portage Q3 2016 Chairman’s Letter

read more

Portage Announces Appointment of New Director

read more

Biohaven Commences Clinical Testing of BHV-4157

read more

Transcript of July 14th Conference Call

read more

FDA clears Biohaven’s Investigational New Drug Application For BHV-4157 and Portage To Hold Investor Conference Call to Provide Business Update

read more

Portage’s Further Investment in Biohaven

read more

Portage’s Biohaven Orphan Drug Designation Request Granted for the Treatment of Spinocerebellar Ataxia

read more

Portage’s Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction with FDA

read more

Portage’s Biohaven Announces Positive Results from Phase I Study with BHV-0223

read more

Mr. James Mellon and Dr. Gregory Bailey (“Offerors”) Announce Additional Shares in Portage Biotech Inc.

read more

Portage’s Biohaven Announce Phase I Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223 and also Appoints a CEO

read more

Portage’s Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223

read more

Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research

read more

Portage’s Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223

read more

Portage’s PPL Will Advance its Lead Candidate PPL-003 to an IND for Dry Eye Disease and Uveitis

read more

Portage’s Biohaven Doses First Human Subject in Phase I Trial with Lead Drug Candidate BHV-0223

read more

Portage’s Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC

read more

Portage’s Biohaven Raises US$4.1 Million in First Tranche of Private Placement. Portage Invests $2.5M

read more

Portage Invests in Sentien Biotechnologies, Inc.

read more

Portage’s Biohaven Announces IND Filing for BHV-0223 for Phase I Clinical Testing

read more

Portage Completes Non-Brokered Private Placement in Two Tranches for Total Proceeds of US$ 5,155,080

read more

Portage Closes First Tranche of Private Placement

read more

Portage’s Biohaven to Begin Phase I Study in 3Q 2015 and Readying for Phase III Study Start by Q1 2016

read more

Portage’s CPP Platform Delivers a Peptide Cargo Across the Blood Brain Barrier

read more

Portage to Present at Master Investor 2015 UK

read more

Portage’s Biohaven Announces Agreement with Inventiv Health

read more

Portage’s Biohaven Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product

read more

Portage’s Biohaven Receives Response from FDA to its Pre-IND Meeting Request

read more

Portage Announces Further Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology

read more

Portage Completes Non-Brokered Private Placement for Total Proceeds of US$2,000,000

read more

Portage Announces Additional Consultants to Expedite its PPL-003 Development Programs

read more

Portage Announces Conversion of Its Debt into Equity

read more

Portage Announces New Consultants for its PPL-003 Development Programs

read more

Portage Announces Proposed Private Placement

read more

Portage’s Biohaven Granted United States Patent for Glutamate Agents in the Treatment of Mental Disorders

read more

Portage Announces Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology

read more

Portage Signs a Collaborative Research and Development Agreement with U.S. National Institute of Health

read more

Portage’s Biohaven Issued Notice of Allowance: Glutamate Agents in the Treatment of Mental Disorders

read more

Portage Provides Updates

read more

Yale University Reports on Biohaven

read more

Portage Reports Third Quarter Financial Results and Provides Updates

read more

Portage Acquires Majority Interest in Biohaven Pharmaceutical Holding Company Limited

read more

Portage Lauches New Website and Provides Update on its R&D Activities

read more

Correction to October 25th Release

read more

Portage Announces Listing on Canadian National Stock Exchange

read more

Portage Biotech Inc’s Name Change and New Trading Symbol Approved by FINRA

read more

Bontan Changes its Name to Portage Biotech Inc. and Jurisdiction to BVI

read more

Bontan Closes Portage Pharma Limited Acquisition

read more

Bontan Provides Update on Letter of Intent with Portage Pharma Ltd.

read more

Bontan Incorporates a Subsidiary in the British Virgin Islands

read more

Bontan Signs Letter of Intent

read more
Load more
Portage Biotech, Inc.
Portage Biotech Inc.
Craigmuir Chambers, Road Town,
Tortola, British Virgin Islands, VG1110
416.929.1806
ian@portagebiotech.com


Portage Biotech, Inc.

Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top